Type I insulin-like growth factor receptor as a therapeutic target in cancer

Bradley S. Miller; Douglas Yee

doi:10.1158/0008-5472.CAN-05-2752

Type I insulin-like growth factor receptor as a therapeutic target in cancer

Bradley S. Miller, Douglas Yee

Research output: Contribution to journal › Review article › peer-review

101 Scopus citations

Abstract

Data from experimental model systems and population studies have implicated type I insulin-like growth factor receptor (IGF1R) signaling in many different human cancers. Drugs to disrupt IGF1R function have been developed and are now entering clinical trial. This brief review will identify key areas to consider as these clinical trials move forward.

Original language	English (US)
Pages (from-to)	10123-10127
Number of pages	5
Journal	Cancer Research
Volume	65
Issue number	22
DOIs	https://doi.org/10.1158/0008-5472.CAN-05-2752
State	Published - Nov 15 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1158/0008-5472.CAN-05-2752

Find It

Find It at U of M Libraries

Cite this

@article{6fc95f88820d4a1d8ffbcf9df9cc8ff3,

title = "Type I insulin-like growth factor receptor as a therapeutic target in cancer",

abstract = "Data from experimental model systems and population studies have implicated type I insulin-like growth factor receptor (IGF1R) signaling in many different human cancers. Drugs to disrupt IGF1R function have been developed and are now entering clinical trial. This brief review will identify key areas to consider as these clinical trials move forward.",

author = "Miller, {Bradley S.} and Douglas Yee",

year = "2005",

month = nov,

day = "15",

doi = "10.1158/0008-5472.CAN-05-2752",

language = "English (US)",

volume = "65",

pages = "10123--10127",

journal = "Cancer Research",

issn = "0008-5472",

number = "22",

}

TY - JOUR

T1 - Type I insulin-like growth factor receptor as a therapeutic target in cancer

AU - Miller, Bradley S.

AU - Yee, Douglas

PY - 2005/11/15

Y1 - 2005/11/15

N2 - Data from experimental model systems and population studies have implicated type I insulin-like growth factor receptor (IGF1R) signaling in many different human cancers. Drugs to disrupt IGF1R function have been developed and are now entering clinical trial. This brief review will identify key areas to consider as these clinical trials move forward.

AB - Data from experimental model systems and population studies have implicated type I insulin-like growth factor receptor (IGF1R) signaling in many different human cancers. Drugs to disrupt IGF1R function have been developed and are now entering clinical trial. This brief review will identify key areas to consider as these clinical trials move forward.

UR - http://www.scopus.com/inward/record.url?scp=28544444712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28544444712&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-2752

DO - 10.1158/0008-5472.CAN-05-2752

M3 - Review article

C2 - 16287993

AN - SCOPUS:28544444712

VL - 65

SP - 10123

EP - 10127

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 22

ER -

Type I insulin-like growth factor receptor as a therapeutic target in cancer

Abstract

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this